Envestnet Portfolio Solutions Inc. Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Envestnet Portfolio Solutions Inc. raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 30.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 16,159 shares of the medical device company’s stock after buying an additional 3,778 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in DexCom were worth $1,257,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of DXCM. Versant Capital Management Inc acquired a new position in DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA boosted its holdings in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after buying an additional 245 shares in the last quarter. Larson Financial Group LLC grew its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the period. Heck Capital Advisors LLC purchased a new position in DexCom in the fourth quarter valued at $38,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of DexCom in the fourth quarter worth about $49,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. The trade was a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock valued at $8,044,178 over the last quarter. 0.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DXCM. Citigroup lifted their price target on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Stock Down 1.7 %

Shares of DXCM opened at $73.80 on Friday. The stock has a fifty day simple moving average of $83.33 and a two-hundred day simple moving average of $76.98. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $28.84 billion, a PE ratio of 51.61, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.